Trial reportLeukemia2005
Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia.
Trial report in Leukemia, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 122 citations in OpenAlex.
- Trial
- Review
- Apoptotic vesicles in cancer: research progress in physiology and therapy.Cell communication and signaling : CCS · 2026Review
- Targeting RHAMM in Cancer: Crosstalk with Non-Coding RNAs and Emerging Therapeutic Strategies Including Peptides, Oligomers, Antibodies, and Vaccines.International journal of molecular sciences · 2025Review
- Recent Progress in Developing Extracellular Vesicles as Nanovehicles to Deliver Carbohydrate-Based Therapeutics and Vaccines.Vaccines · 2025Review
- The Extra-Tumoral Vaccine Effects of Apoptotic Bodies in the Advancement of Cancer Treatment.Small (Weinheim an der Bergstrasse, Germany) · 2025Review
- Advances in biological functions and applications of apoptotic vesicles.Cell communication and signaling : CCS · 2023Review
- Comparison of immunotherapy mediated by apoptotic bodies, microvesicles and exosomes: apoptotic bodies' unique anti-inflammatory potential.Journal of translational medicine · 2023Review
- Apoptotic bodies: bioactive treasure left behind by the dying cells with robust diagnostic and therapeutic application potentials.Journal of nanobiotechnology · 2023Review
- Mixed cultures of allogeneic dendritic cells are phenotypically and functionally stable - a potential for primary cell-based "off the shelf" product generation.Central-European journal of immunology · 2021Article
- Unleashing the therapeutic potential of apoptotic bodies.Biochemical Society transactions · 2020Review
- Induction of Antitumor Immunity by Exosomes Isolated from Cryopreserved Cord Blood Monocyte-Derived Dendritic Cells.International journal of molecular sciences · 2020Article
- Extracellular Vesicles Derived From Apoptotic Cells: An Essential Link Between Death and Regeneration.Frontiers in cell and developmental biology · 2020Review
- Can Dendritic Cell Vaccination Prevent Leukemia Relapse?Cancers · 2019Review
- Mobilizing Immune Cells With Exercise for Cancer Immunotherapy.Exercise and sport sciences reviews · 2017Review
- Dendritic Cell Therapies for Hematologic Malignancies.Molecular therapy. Methods & clinical development · 2017Review
- Use of Cell-Penetrating Peptides in Dendritic Cell-Based Vaccination.Immune network · 2016Review
- Paradigm shifts in the management of poor-risk chronic lymphocytic leukemia.Leukemia & lymphoma · 2015Review
- B-CLL cells acquire APC- and CTL-like phenotypic characteristics after stimulation with CpG ODN and IL-21.International immunology · 2014Article
- Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies.Human vaccines & immunotherapeutics · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, immunotherapies with allogeneic dendritic cells (DCs) pulsed with tumor antigens to generate specific T-cell responses have been tested in clinical trials for patients with solid tumors. This is the first report on a clinical vaccination study with DCs for patients with B-cell chronic lymphocytic leukemia (B-CLL). The potential of allogeneic DCs pulsed ex vivo with tumor cell lysates or apoptotic bodies to stimulate antitumor immunity in patients with B-CLL in early stages was evaluated. Monocyte-derived DCs were obtained from unrelated healthy donors. Nine patients (clinical stage 0 and 1 according to Rai) were vaccinated five times with a mean number of 32 x 10(6) stimulated DCs administered intradermally once every 2-3 weeks. No signs of autoimmunity were detected, and only mild local skin reactions were noted. During the treatment period, we observed a decrease of peripheral blood leukocytes and CD19+/CD5+ leukemic cells. In one patient, a significant increase of specific cytotoxic T lymphocytes against RHAMM/CD168, a recently characterized leukemia-associated antigen, could be detected after DC vaccination. Taken together, the study demonstrated that DC vaccination in CLL patients is feasible and safe. Immunological and to some extent hematological responses could be noted, justifying further investigation on this immuno-therapeutical approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.